evidence table
Fish Oil Inflammation Randomized Trial Evidence Table
Structured evidence table for Fish Oil Inflammation Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Fish Oil Inflammation Randomized Trial | Results At the end of the 12-week trial, gait speed significantly increased in the Arg + fish oil groups ( p p p p Conclusion Supplementing with both arginine and fish oil significantly boosted muscle strength, physical performance, and reduced levels of inflammation in older adults with sarcopenia. | 2 | Yuan W (2026) | Twelve-week combined arginine and fish oil supplementation is associated with reduced sarcopenia severity: a randomized, double-blind, placebo-controlled study. |
| Fish Oil Inflammation Randomized Trial | Background Sarcopenia is a geriatric syndrome characterized by the gradual loss of skeletal muscle mass and function, posing a major public health concern due to its link to various negative health outcomes. | 2 | Yuan W (2026) | Twelve-week combined arginine and fish oil supplementation is associated with reduced sarcopenia severity: a randomized, double-blind, placebo-controlled study. |
| Fish Oil Inflammation Randomized Trial | While supplementation with arginine or fish oil has shown potential in reducing muscle loss and functional decline, the combined effects of arginine and fish oil supplementation in sarcopenia remain largely unexplored. | 2 | Yuan W (2026) | Twelve-week combined arginine and fish oil supplementation is associated with reduced sarcopenia severity: a randomized, double-blind, placebo-controlled study. |
| Fish Oil Inflammation Randomized Trial | Over time, however, increased rates of exaggerated inflammatory responses began to be reported in critically ill patients and in individuals receiving long-term parenteral nutrition, and excessive omega-6 fatty-acid delivery was considered a likely contributor to these adverse effects. | 4 | Kęska Mariusz (2026) | Fish Oil-Containing Injectable Lipid Emulsions in Parenteral Nutrition: Immunomodulation and Clinical Outcomes in Critically Ill Patients—Narrative Review |
| Fish Oil Inflammation Randomized Trial | This article is a narrative review that aims to synthesize the mechanistic rationale and clinically relevant evidence regarding fish oil-containing injectable lipid emulsions (FO-ILE) used in parenteral nutrition (PN), with a focus on critically ill adult patients. | 4 | Kęska Mariusz (2026) | Fish Oil-Containing Injectable Lipid Emulsions in Parenteral Nutrition: Immunomodulation and Clinical Outcomes in Critically Ill Patients—Narrative Review |
| Fish Oil Inflammation Randomized Trial | In addition, reference lists of relevant clinical trials, meta-analyses, and guideline/consensus documents were screened to identify further key publications. | 4 | Kęska Mariusz (2026) | Fish Oil-Containing Injectable Lipid Emulsions in Parenteral Nutrition: Immunomodulation and Clinical Outcomes in Critically Ill Patients—Narrative Review |
| Fish Oil Inflammation Randomized Trial | 1 2 1 Since the development of the first-generation total parenteral nutrition (TPN) in the 1960s, injectable lipid emulsions have been a key component, providing both energy and essential fatty acids [,]. | 4 | Kęska Mariusz (2026) | Fish Oil-Containing Injectable Lipid Emulsions in Parenteral Nutrition: Immunomodulation and Clinical Outcomes in Critically Ill Patients—Narrative Review |
Source documents
- Twelve-week combined arginine and fish oil supplementation is associated with reduced sarcopenia severity: a randomized, double-blind, placebo-controlled study.
- Fish Oil-Containing Injectable Lipid Emulsions in Parenteral Nutrition: Immunomodulation and Clinical Outcomes in Critically Ill Patients—Narrative Review